However, a significant increase in tumor-infiltrating lymphocytes (TILs) was observed in tumors treated with OAd-MSCs (Figure 4A), as well as a significant reduction of the CD4+/CD8+ ratio, due to the reduced and increased levels of CD4+ and CD8+ T cells, respectively (Figure 4B). The gene discussed is CD8A; the disease is neoplasm.